BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

22 أبريل 2024 06:45:00 بحسب Nasdaq GlobeNewswire

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

07 أبريل 2024 14:00:00 بحسب Nasdaq GlobeNewswire

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

20 مارس 2024 06:15:00 بحسب Nasdaq GlobeNewswire

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

20 مارس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

11 مارس 2024 07:45:00 بحسب Nasdaq GlobeNewswire

BioNTech Announces Planned Retirement of Sean Marett

07 مارس 2024 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

06 مارس 2024 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 

08 فبراير 2024 05:45:00 بحسب Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

31 يناير 2024 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

22 يناير 2024 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

09 يناير 2024 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

21 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

18 ديسمبر 2023 13:15:00 بحسب Nasdaq GlobeNewswire

BioNTech to Inaugurate First African Site on December 18, 2023

12 ديسمبر 2023 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

06 نوفمبر 2023 06:45:00 بحسب Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

26 أكتوبر 2023 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

23 أكتوبر 2023 11:30:00 بحسب Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

23 أكتوبر 2023 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

19 أكتوبر 2023 06:45:00 بحسب Nasdaq GlobeNewswire

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

16 أكتوبر 2023 03:30:00 بحسب Nasdaq GlobeNewswire